Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer - Wardley, A M; Pivot, X; Morales-Vasquez, F (J Clin Oncol, 2010)